A Multicenter Double Blind Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar? Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis
The purpose of this study is to determine if adding Acthar to riluzole will further help by either slowing down how fast ALS symptoms progress and/or increasing the time before you die.
The purpose of this study is to examine the effect of Acthar on decline in adult subjects with ALS.
- IRB Number: 1703907333
- Research Study Identifier: TX8017
- Principal Investigator: Cynthia Bodkin, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required